Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial - PubMed
3 days ago
- #chronic kidney disease
- #genetic testing
- #hypertension
- The GUARDD-US trial investigated the impact of providing APOL1 high-risk genotype results on blood pressure management and CKD screening in adults with hypertension and African ancestry.
- Participants were randomized to receive APOL1 results immediately (intervention) or after 6 months (control).
- No overall difference in systolic blood pressure (SBP) reduction was observed between the intervention and control groups at 3 months.
- Subgroup analysis showed significant SBP reduction (-4.1 mm Hg) in the intervention group among individuals with uncontrolled BP.
- APOL1 genotype disclosure increased urine microalbumin screening (17.3% difference) and new CKD diagnoses (5.7% difference) at 6 months.
- The study suggests that APOL1 genetic testing may benefit individuals with uncontrolled hypertension but requires further investigation.